Doxorubicin (Dox) is a secondary metabolite of the mutated strain of Streptomyces peucetius
var. Caesius and belongs to the anthracyclines family. The anti-cancer activity of Dox is …

The production of reactive species is a core of the redox cycling profile of anthracyclines.
However, these molecular characteristics can be viewed as a double‐edged sword acting …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Heart failure is a common, costly, and debilitating syndrome that is associated with a highly
complex drug regimen, a large number of comorbidities, and a large and often disparate …

Background: Cancer therapy–induced cardiomyopathy (CCM) is associated with cumulative
drug exposures and preexisting cardiovascular disorders. These parameters incompletely …

Anthracycline compounds are major culprits in chemotherapy-induced cardiotoxicity, which
is the chief limiting factor in delivering optimal chemotherapy to cancer patients. Although …

In metastatic breast cancer (MBC), the conventional doxorubicin (DOX) has various
problems due to lack of selectivity with subsequent therapeutic failure and adverse effects …

The utility of anthracycline antineoplastic agents in the clinic is compromised by the risk of
cardiotoxicity. It has been calculated that approximately 10% of patients treated with …

Anthracyclines are the cornerstone of many chemotherapy regimens for a variety of cancers.
Unfortunately, their use is limited by a cumulative dose-dependent cardiotoxicity. Despite …

The interindividual genetic variations in drug metabolizing enzymes and transporters
influence the efficacy and toxicity of numerous drugs. As a fundamental element in precision …